role in the conversion of stable coronary artery disease (CAD) to ACS. [6] [7] [8] The role of lymphocyte function in ACS is less clearly defined. Previous studies in humans suggest that ACS may be accompanied by perturbed cytokine production, [9] [10] [11] [12] [13] but the underlying mechanisms accounting for these changes have not been established. We have previously reported that ACS is accompanied by an expansion of inflammatory monocytes akin to findings in HIV disease; however, this was not accompanied by evidence of CD8 T-cell activation as measured by the expression of human leukocyte antigen (HLA)-DR. 14 We sought to analyze, in fine detail, lymphocyte phenotypes in patients presenting with ACS. Because T-lymphocyte function depends critically on whether the cell has previously been exposed to its cognate antigen, we sought to determine whether ACS might be accompanied by relative differences in maturation populations (naïve, effector, terminal effector, effector memory, and central memory), and whether the cytokine production among corresponding subpopulations is perturbed in ACS.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Imbalance of CD8 + Maturation Subsets in ACS
To evaluate the possibility that ACS is associated with changes in the relative frequencies of CD8 + T-cell subpopulations, peripheral blood mononuclear cells (PBMCs) from patients with ACS and patients with stable CAD were analyzed for phenotype and function by polychromatic flow cytometry. CD8 + naïve, effector, terminal effector, effector memory, and central memory subpopulations were defined using standard phenotypic markers including CD45RO, CD27, and CD57, using the sequential gating strategy shown (Figure 1 ). To minimize the possibility of type I error, significant differences observed in the pilot cohort were tested in a replication cohort. The baseline demographic and clinical characteristics of these patients are displayed in Table 1 .
Within the CD8 niche, differences among maturation subsets were apparent in the pilot and replication studies ( Figure  2A ). The proportion of CD8 + T cells that were phenotypically naïve (CD27 + /CD45RO − ) was lower in patients with ACS (ACS, 28.4 versus control, 37.2%, *P=0.019). In the replication cohort ( Figure 2B ), the proportion of cells with a naïve surface phenotype was once again reduced in patients with ACS when compared with patients with stable CAD (ACS, 13 .3% versus control, 29.1%; **P=0.001). There were no outliers (as defined by having an absolute standardized value >3.29). Taking the pilot and replication cohorts together, the mean difference in the proportion of naïve CD8 T cells was similarly significant after adjustment for age, sex, diabetes mellitus, smoking status, and cohort ( Table 2) .
Patients with ACS in the pilot cohort had significantly more CD8 + effector memory (CD27 − /CD45RO + ) cells (ACS, 19.5% versus control, 9.9%; *P=0.009) than control subjects. This was also observed in the replication cohort wherein effector memory cells were again found to be increased in ACS (ACS, 19.9% versus control, 14.7%; *P=0.017). There were no outliers. Taking the pilot and replication cohorts together, the mean difference in the proportion of effector memory CD8 T cells was similarly significant after adjustment for age, sex, diabetes mellitus, smoking status, and cohort ( Table 2) .
Patients with ACS had significantly more CD8 + effector (CD57 + /CD45RO + ) cells (ACS, 9.4% versus control, 4.0%; *P=0.002) in the pilot study, but this was not observed in the replication cohort (ACS, 10.2% versus control, 11.4%; P=0.370).
The percentage of CD8 + central memory (CD27 + / CD45RO + ; ACS, 28.8% versus control, 21.7%; P=0.312) and terminal effector (CD57 + /CD45RO − ; ACS, 22.8% versus control, 5.5%; P=0.096) cells was not significantly different in patients with ACS when compared with control patients.
These data suggest that within the CD8 niche, ACS is associated with an imbalance of maturation distributions with diminished proportions of naïve and a relative expansion of effector memory CD8 + T lymphocytes.
Altered Cytokine Production by CD8 + T Cells in ACS
We next evaluated the profile of cytokine production by CD8 + T-cell populations, comparing corresponding maturation subsets in patients with ACS and stable CAD. The production of IL-2 and IFNγ after stimulation via the T-cell receptor (TCR) in the presence of costimulation was determined by intracellular staining and quantified separately for naïve cells, total effector cells (the aggregate of effector and terminal effector subsets), and total memory cells (the aggregate of effector memory and central memory cells).
In the pilot study, CD8 + naïve cells from patients with ACS had lower proportions of IL-2 + /IFNγ − cells when compared with naïve cells from control patients (ACS, 0.9% versus control, 2.7%; *P=0.026; Figure 3A ). Similarly, in the replication cohort, the IL-2 + /IFNγ − response of naïve CD8 T cells in ACS was significantly reduced (ACS, 0.5% versus control, 1.7%; *P=0.018; Figure 3D ). There was 1 high outlier among the patients with ACS in the pilot cohort as shown whose inclusion/exclusion does not have a notable effect on the calculated significance (**P=0.008 when outlier excluded). Taking the pilot and replication cohorts together, the mean difference in the proportion of IL-2 + /IFNγ − CD8 T cells among the naïve population was similarly significant after adjustment for age, sex, diabetes mellitus, smoking status, and cohort ( Naïve cells from patients with ACS tended to have a higher proportion of IL-2 − /IFNγ + cells when compared with controls (ACS, 9.1% versus control, 5.1%; P=0.048) in the pilot study ( Figure 3A) but not in the replication study (ACS, 2.2% versus control, 3.1%; P=0.361). ACS was not associated with differences in the proportion of multifunctional IL-2 + /IFNγ + cells (ACS, 2.4% versus control, 2.6%; P=1.000) within this naïve subpopulation. Thus, CD8 + naïve cells from patients with ACS displayed an altered cytokine production profile characterized by reduced frequency of IL-2 + /IFNγ − cells compared with CD8 + naïve cells from control patients.
As anticipated, the cytokine profile of total effector CD8 + T cells differed from that of naïve cells in that these subsets expressed no significant IL-2, but exhibited robust IFNγ responses ( Figure 3B ). There was no difference in the proportions of IL-2 + /IFNγ − cells (ACS, 0.03% versus control, 0.09%; P=0.056), IL-2 − /IFNγ + cells (ACS, 24.6% versus control, 22.0%; P=0.796), or IL-2 + /IFNγ + cells (ACS, 3.3% versus control, 3.6%; P=0.666). Thus, CD8 + effector cells did not demonstrate an altered cytokine profile when compared with corresponding effector cells in control patients. Memory cells were capable of efficient production of both IL-2 and IFNγ ( Figure 3C ). When compared with controls, memory cells from patients with ACS had lower proportions of IL-2 + /IFNγ − cells (ACS, 2.7% versus control, 7.4; *P=0.019) in the pilot cohort, but not in the replication ( Figure 3D ) study (ACS, 1.0% versus control, 2.2%; P=0.343). The proportions of IL-2 − /IFNγ + cells in ACS were not significantly different (ACS, 20.0% versus control, 13.7; P=0.064). The proportions of multifunctional IL-2 + /IFNγ + cells (ACS, 11.8% versus control, 10.7; P=0.931) were similar in patients with ACS when compared with controls.
Naïve CD8 + T-Cell Homeostasis in ACS
A consistent feature of both the pilot and replication studies was that naïve CD8 T cells were reduced, both in number and in function vis à vis IL-2 production. Taking these 2 features in combination, the proportion of naïve IL-2 + /IFNγ − cells, as a percentage of total CD8 lymphocytes, is markedly reduced in ACS (ACS, 0.18% versus control, 1.04%; **P=0.001, ***P<0.001 excluding outlier), replication cohort (ACS, 0.11% versus control, 0.71%; **P=0.003), and total population (ACS, 0.16% versus control, 0.75%; ***P<0.001; Figure  IA -IC in the online-only Data Supplement).
Oxidized Low-Density Lipoprotein Leads to PD-1 Expression and Loss of IL-2 Production In Vitro
The loss of IL-2 production and apoptosis can be associated with the expression of PD-1 in the setting of immune exhaustion. [15] [16] [17] [18] [19] Because the pathophysiology of ACS is thought to be mediated, in part, by responses to proinflammatory lipids such as oxidized low-density lipoproteins (ox-LDL), 6, 20 we sought to determine whether exposure to ox-LDL might regulate CD8 T-cell expression of PD-1 and IL-2. PBMC from healthy volunteers were incubated for 18 hours in medium alone, lipopolysaccharide (20 ng/mL), thrombospondin-1 (10 μg/mL), LDL (100 μg/mL), or ox-LDL (10 and 100 μg/mL), and the expression of PD-1 on CD8 + T cells was analyzed by flow cytometry (Figure 4 ). There is no effect of lipopolysaccharide, thrombospondin -1, or unmodified LDL on PD-1 expression, but exposure to ox-LDL leads to increased expression of PD-1 by CD8 T cells (mean % PD-1±SEM: NS=25.4±3.4% versus ox-LDL 100 μg/mL=44.1±6.5). The effect of oxidized LDL was also apparent on phenotypically naïve (CD27 + CD45RO − ) CD8 T cells ( Figure II in the online-only Data Supplement). Similar results were obtained when purified CD8 T cells were stimulated with oxidized LDL, suggesting that the upregulation may be because of a direct effect of oxidized LDL on CD8 T cells ( Figure III in the online-only Data Supplement).
Next, we sought to determine whether exposure to ox-LDL affects TCR-stimulated IL-2 production. Purified CD8 T cells from healthy volunteers were incubated for 18 hours in medium with or without ox-LDL (100 μg/mL) before stimulation with plate-bound CD3/CD28 or medium for an additional 18 hours. The supernatants from these conditions were then analyzed for IL-2 protein using cytometric bead assays ( Figure 5A ). Incubation with ox-LDL led to a significant reduction in IL-2 secretion (40.8±10.1%). To determine the effects of ox-LDL on naïve CD8 T cells, similar experiments were performed, and IL-2 was analyzed by flow cytometry using intracellular staining. PBMC from healthy volunteers were incubated for 18 hours in medium alone or ox-LDL (100 μg/mL) before stimulation with plate-bound CD3/CD28 or medium for an additional 6 hours. Naïve CD8 + T cells were analyzed for PD-1 expression ( Figure 5B ) and IL-2 expression ( Figure 5C ). Stimulation of PBMC with ox-LDL, with or without TCR stimulation, led to a significant increase in PD-1 expression by naïve CD8 T cells, an effect that was independent of TCR stimulation (mean % of PD-1 + cells (±SEM): NS/NS=9.2±1.7%, ox-LDL/ NS=17.5±2.3%, NS/CD3 + CD28=6.6±2.0%, and ox-LDL/ CD3 + CD28=19.3±2.6%). Stimulation with ox-LDL before TCR stimulation lead to a significant reduction in the percentage of IL-2 + /IFNγ − naïve CD8 T cells after TCR stimulation (mean % of IL-2 + cells (±SEM): NS/NS=0.96±0.05, ox-LDL/ NS=1.48±0.24, NS/CD3 + CD28=2.23±0.17%, ox-LDL/ CD3 + CD28=1.56±0.17).
These results suggest that elevated levels of ox-LDL in ACS, as has been observed both in atheroma 21 and systemically, 22 could impart an immunoregulatory effect on CD8 T cells and account for the reduction in IL-2 production we observe in patients with ACS.
ACS Is Associated With Increased PD-1 Expression by CD8 + Naïve T Cells
We next sought to determine whether PD-1 expression by naïve CD8 T cells differs in patients with ACS when compared with controls. Cryopreserved PBMC from patients in the replication cohort were analyzed by flow cytometry for the expression of PD-1 by naïve CD8 + T cells ( Figure 6A ). ACS was associated with an increase in PD-1 + cells when compared with controls (controls, 8.0% versus ACS, 13.25%; *P=0.023, *P=0.037 with outlier excluded). The PD-1 expression by naïve CD8 T cells correlated inversely with stimulated IL-2 production in naïve CD8 + T cells ( Figure 6B ; Spearman r=−0.440; *P=0.012, *P=0.016 with outlier excluded). These results are consistent with the notion that the loss of IL-2 production observed in patients with ACS may be indicative of an immune exhaustion phenotype among naïve CD8 T cells.
Discussion
Herein, we report that ACS is associated with altered proportions of naïve and effector memory subsets within the CD8 + T lymphocyte compartment. Patients with ACS had a relative reduction in naïve CD8 + T cells and expansion of effector memory cells. Although effector and memory cells were better producers of IFNγ than naïve cells, we observed no consistent difference in IFNγ production by naïve, effector, or memory subsets in ACS when compared with corresponding maturation subsets in stable patients. However, naïve cells from patients with ACS were impaired in their production of IL-2, a cytokine of fundamental importance whose autocrine production is required for T-cell replication and protective responses to antigen. 23, 24 These were unexpected findings, leading us to confirm these observations prospectively in a separate cohort. Furthermore, we find that the impairment of IL-2 production by naïve CD8 cells correlates with increased PD-1 expression, a marker of immune exhaustion. In vitro, exposure to oxidized LDL recapitulates these phenotypic and functional features.
The homeostatic maintenance of naïve and memory niches is critical for the capacity to response to new and old antigens, respectively, and thus determine the host response to infection or vaccination. 25 The production of IL-2 by naïve cells is required for TCR activation, proliferation, and differentiation into effector and ultimately memory cells. 26 Autocrine IL-2 production is also critical for the recall response and secondary expansion of memory cells.
We hypothesized that ACS might be associated with an altered balance between naïve and effector/memory cells for several reasons. First, ACS has previously been associated with enhanced cytokine production by T lymphocytes. [27] [28] [29] For instance, Liuzzo et al 27 found that T cells display enhanced expression of IFNγ and reduced expression of IL-2 in ACS. Previous work has also suggested that TCR signaling is hyperresponsive in ACS. 13 Moreover, ACS has been associated with reduced expression of CCR7, 30 a chemokine receptor that is highly expressed on naïve and central memory T cells but not on effector or effector memory cells. These studies measured changes among total CD4 or CD8 T lymphocytes, but did not account for potential shifts in the balance of naïve and effector/memory T-cell subsets. Our hypothesis was that ACS would be accompanied by a relative expansion of effector and memory T cells, which would be consistent with these previous observations.
We did indeed observe a relative decrease in naïve cells and an increase in effector memory cells. Several processes could account for the altered proportions of CD8 + subsets we observed, including redistribution of cells, expansion of effector memory cells, and decreased proliferation or survival of naïve cells. Additional study is, therefore, needed to determine the mechanism of this altered homeostasis, whether this is transient or sustained, and its effect on host responses to potential intercurrent illness. Given the temporal association between myocardial infarction and acute upper respiratory Purified CD8 T cells were incubated for 18 h with or without ox-LDL (100 μg/mL) and then stimulated with anti-CD28 and plate-bound antibodies to CD3 for an additional 18 h. The supernatant was analyzed for the secretion of IL-2 using cytometric bead assays. IL-2 production was quantified as the percentage of maximal stimulation obtained with CD3/CD28 in the absence of ox-LDL (A). Peripheral blood mononuclear cells were incubated for 18 h with or without ox-LDL (100 μg/mL), and then cells were stimulated using plate-bound antibodies to CD3/CD28 for an additional 6 h. The expression of PD-1 (B) and IL-2 (C) by naïve CD8 + T cells are plotted (repeated-measures ANOVA, Bonferroni post hoc tests; *P<0.05, ***P<0.001).
tract illnesses, 31 these data raise the possibility that the immune status of ACS could make patients more susceptible to such illnesses instead of (or in addition to) the reverse.
Chronic inflammation and cancer can be accompanied by a functional impairment of antigen-dependent CD8 T-cell responses, a phenomenon termed immune exhaustion. This phenotype refers to a progressive, hierarchical loss of T-cell functions including IL-2 production, proliferative potential, inflammatory cytokine production, and ultimately apoptosis of antigen-experienced cells. This phenotype can be attenuated by inhibiting the PD-1 pathway, among other checkpoint receptors, which negatively regulate TCR signaling. This strategy has demonstrated clinical efficacy in the treatment of cancer 32 and has the potential to improve the treatment of HIV 33, 34 and viral hepatitis. 35 Whether exhaustion pathways impact the pathogenesis of atherosclerosis has not yet been established. Previous works have demonstrated that genetic deletion of PD-1 or its ligands increases atherosclerosis in LDL receptor knockout mice. 36, 37 These mice experience increased influx of monocytes, CD4 T cells, and CD8 T cells in association with increased tumor necrosis factor-α. However, the role of PD-1 ligation in human atherosclerosis remains uncertain. [38] [39] [40] It is against this background that we find phenotypically naive CD8 T cells from patients with ACS have a reduced capacity for IL-2 production, and this correlates with increased expression of PD-1. Memory (CD45 + ) cells from patients with ACS also a tended to have reduced IL-2 expression. These data raise the possibility that features of immune exhaustion may pervade the inflammatory milieu in ACS, best demonstrable within the CD27 + /CD45RO − niche. It is important to highlight that we used standard surface markers to assign maturation status to control for differences in the proportion of naïve cells when comparing cytokine responses. These markers are imperfect, and thus additional study using expanded panels is warranted to determine with greater granularity the phenotypic and functional differences with particular attention to markers of exhaustion in combination with previous antigen exposure.
Immune exhaustion typically develops under conditions of antigen persistence. Factors such as duration and magnitude of TCR stimulation have been shown to control PD-1 expression. 2, 17 Less well understood are potential extrinsic factors that promote immune exhaustion. 2,41 Therefore, we sought to test, in vitro, potential mediators relevant to ACS for effects on PD-1 expression and IL-2 production by CD8 T cells. Our observations that ox-LDL upregulates PD-1 expression and suppresses IL-2 production raises the possibility that exhaustive pathways can be triggered independent of exposure to cognate antigen. This finding is of potential clinical relevance in cancer and chronic viral infections whose pathogenesis can be complicated by immune exhaustion. For instance, the notion that suppression of LDL or the oxidation thereof could limit exhaustion is supported by a recent report that rosuvastatin reduces PD-1 expression in patients with HIV. 42 This may suggest that current and future therapies for LDL lowering might help reverse peripheral tolerance.
Ox-LDL is capable of activating cells via an expanding array of cell surface receptors including toll-like receptors and scavenger receptors, such as CD36 and lectin-like ox-LDL receptor-1. These pathways have generally been studied in the context of immune activating pathways by ox-LDL on endothelial cells, platelets, and monocyte/macrophages. Additional study is, therefore, needed to determine the relevant signaling pathways triggered by ox-LDL in CD8 T cells. Also, because PD-1 is one of several checkpoint receptors that mediate exhaustion, a more complete understanding of the phenotypic and functional effects of these oxidized lipoproteins is needed. In light of the proinflammatory effects of ox-LDL for innate immune activation, it is tempting to speculate that these negative regulatory effects of ox-LDL may represent a mechanism to limit the proinflammatory effects on monocytes and prevent autoimmunity under conditions of oxidative stress.
Finally, these data and the recent observations of others 36, 37, 39, 40, 42 raise the possibility that immune exhaustion pathways may have relevance to the progression and activity of atherosclerosis in humans. Additional studies are needed to determine whether PD-1 inhibition alters the course of cardiovascular diseases. Proof of either causal or protective relationships between these exhaustion pathways and ACS could signal the potential for novel treatments of atherosclerotic cardiovascular disease.
Limitations and Strengths
We sought to assess the feasibility of conducting fine analysis of T lymphocytes in patients with ACS using polychromatic flow cytometry to simultaneously analyze in fine detail both phenotype and function. Several limitations deserve special attention. First, a large number of experimental variables were Figure 6 . Acute coronary syndrome (ACS) is associated increased programmed cell death (PD)-1 expression by naïve CD8 + lymphocytes, which correlates with naïve interleukin (IL)-2 + /IFNγ − production by intracellular staining. A, The expression of PD-1 on naïve CD8 + T cells from patients with ACS is compared with control patients in the replication cohort (Mann-Whitney U, *P<0.01). B, The expression of PD-1 vs IL-2 production among naïve CD8 + T cells is plotted for patients in the replication cohort (Spearman r, *P<0.05). A single outlier (z-score >3.29) is identified with a purple halo, included in the analysis, and discussed in the text. sampled during the pilot phase of this study, relative to patient sample sizes. To mitigate the likelihood for type 1 error in this setting, we confirmed all significant findings in a separate validation study. Another important limitation is that our patients with ACS and stable CAD differed in individual baseline characteristics, which may affect immune phenotypes. We adjusted for some of these variables in our generalized linear model; however, additional studies with larger sample sizes are needed to confirm and extend these findings. In addition, the determination of maturation based on standard surface markers is imperfect, and thus additional studies are needed to characterize the differences in CD8 T-cell subsets in ACS in finer detail.
Conclusions
We present evidence that ACS is accompanied by altered CD8 + T lymphocyte subpopulations, which includes both a relative expansion of antigen-experienced CD8 T cells as well as functional and phenotypic evidence of hyporesponsiveness by naïve CD8 cells. We also describe a heretofore-unrecognized immune effect of ox-LDL that leads to PD-1 expression and negatively regulates IL-2 production by CD8 cells in vitro. These findings imply that ACS may be a more complex immunologic process than previously recognized with both proinflammatory, as well as counter-regulatory immune features. Additional study is needed to determine whether the altered CD8 phenotypes are part cause or consequence of ACS. Additional study is also warranted to determine whether ox-LDL may contribute to immune exhaustion as a part of the pathophysiology of other chronic inflammatory disorders and cancer.
